The identification of critical genes that encode for regulatory proteins has helped elucidate the molecular mechanisms that govern cell proliferation and malignant transformation. Several approaches to gene therapy for cancer have been described. These include the use of fibroblasts expressing suicide genes, restoration of expression of tumor suppressor genes, cytokine gene therapy, genetic modification of T lymphocytes, and protection of normal hemopoiesis in cancer patients. Clinical trials are underway in all these areas.
Get full access to this article
View all access options for this article.
References
1.
HunterT.Cooperation between oncogenes. Cell.1991; 64: 249–270.
ScottO.C.Tumor transplantation and tumor immunity: a personal view. Cancer Res.1991; 51: 757–763.
4.
RosenbergS.A.Immunotherapy and gene therapy of cancer. Cancer Res.1991; 51(Suppl 18): 5074s–5079s.
5.
BoonT.Toward a genetic analysis of tumor rejection antigens. Adv Cancer Res.1992; 58: 177–210.
6.
ArmentanoD., YuS.F., KantoffP.W.Effect of internal viral sequences on the utility of retroviral vectors. J Virol.1987; 61: 1647–1650.
7.
MarkowitzD., GoffS., BankA.Construction and use of a safe and efficient amphotropic packaging cell line. Virology.1988; 167: 400–406.
8.
BlaeseR.M., CulverK.W., AndersonW.F.The ADA human gene therapy clinical protocol. Hum Gene Ther.1990; 1: 327–362.
9.
MoritzT., KellerD.C., WilliamsD.A.Human cord blood cells as targets for gene transfer: potential use in genetic therapies of severe combined immunodeficiency disease. J Exp Med.1993; 178: 529–536.
10.
FishelR., LescoeM.R., RaoM.R.The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell.1993; 75: 1027–1038.
11.
RouleauG.A., MerelP., LutchmanM.Alteration in a new gene encoding a putative membrane-organizing protein causes neurofibromatosis type 2. Nature.1993; 363: 515–521.
12.
OldfieldE.H., RamZ., CulverK.W.Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir. Hum Gene Ther.1993; 4: 39–69.
13.
RamZ., CulverK.W., WalbridgeS.In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. Cancer Res.1993; 53: 83–88.
14.
BiW.L., ParysekL.M., WarnickR.In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV tk retroviral gene therapy. Hum Gene Ther.1993; 4: 725–731.
15.
CulverK.W.Clinical applications of gene therapy for cancer. Clin Chem.1994; 40: 510–512.
16.
RamZ., WalbridgeS., OshiroE.M.Intrathecal gene therapy for malignant leptomeningeal neoplasia. Cancer Res.1994; 54: 2141–2145.
17.
TakahashiT., NauM.M., ChibaI.P53: a frequent target for genetic abnormalitiies in lung cancer. Science.1989; 246: 491–494.
18.
FujiwaraT., GrimmE.A., MukhopadhyayT.A retroviral wild-type p53 expression vector penetrates human lung cancer spheroids and inhibits growth by inducing apoptosis. Cancer Res.1993; 53: 4129–4133.
19.
GeorgesR.N., MukhopadhyayT., ZhangY.Prevention of orthotopic human lung cancer growth by intratracheal instillation of a retroviral antisense K-ras construct. Cancer Res.1993; 53: 1743–1746.
20.
HaseloffJ., GerlachW.L.Simple RNA enzymes with new and highly specific endoribonuclease activities. Nature.1988; 334: 585–591.
21.
Kashani-SabetM., FunatoT., FlorenesV.A.Suppression of the neoplastic phenotype in vivo by an anti-ras ribozyme. Cancer Res1994; 54: 900–902.
22.
SlamonD.J., GodolphinW., JonesL.A.Studies of HER-2/neu proto-oncogene in human breast and ovarian cancer. Science1989; 244: 707–712.
23.
YoshinoI., PeoplesG.E., GoedegebuureP.S.Association of HER2/neu expression with sensitivity to tumor-specific CTL in human ovarian cancer. J Immunol.1994; 152: 2393–2400.
24.
van der BruggenP., TraversariC., ChomezP.A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science.1991; 254: 1643–1647.
25.
KawakamiY., EliyahuS., DelgadoC.H.Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA.1994; 91: 6458–6462.
26.
RosenbergS.A., LotzeM.T., MuulL.M.A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med.1987; 316: 888–897.
27.
RosenbergS.A.PackardBS, AebersoldPM, Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N Engl J Med.1988; 319: 1676–1680.
28.
GansbacherB., ZierK., DanielsB.Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med.1990; 172: 1217–1224.
29.
GolumbekP.T., LazenbyA.J., LevitskyH.I.Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science.1991; 254: 713–716.
30.
PorgadorA., TzehovalE., KatzA.Interleukin 6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells. Cancer Res.1992; 52: 3679–3686.
GansbacherB., BannerjiR., DanielsB.Retroviral vector-mediated γ-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Res.1990; 50: 7820–7825.
DranoffG., JaffeeE., LazenbyA.Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA.1993; 90: 3539–3543.
35.
ColomboM.P., FerrariG., StoppacciaroA.Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo. J Exp Med.1991; 173: 889–897.
36.
StoppacciaroA., MelaniC., ParenzaM.Regression of an established tumor genetically modified to release granulocyte colony-stimulating factor requires granulocyte-T cell cooperation and T cell-produced interferon γ. J Exp Med.1993; 178: 151–161.
37.
CavalloF., GiovarelliM., GulinoA.Role of neutrophils and CD4+ T lymphocytes in the primary and memory response to nonimmunogenic murine mammary adenocarcinoma made immunogenic by IL-2 gene. J Immunol.1992; 149: 3627–3635.
38.
HockH., DorschM., KunzendorfU.Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or interferony. Proc Natl Acad Sci U S A.1993; 90: 2774–2778.
39.
GansbacherB., ZierK., CroninK.Retroviral gene transfer induced constitutive expression of interleukin-2 or interferon-γ in irradiated human melanoma cells. Blood.1992; 80: 2817–2825.
40.
RosenbergS.A., AndersonW.F., BlaeseR.M.Immunization of cancer patients using autologous cancer cells modified by insertion of the gene for interleukin-2. Hum Gene Ther.1992; 3: 75–90.
41.
RosenbergS.A., AndersonW.F., AsherA.L.Immunization of cancer patients using autologous cancer cells modified by insertion of the gene for tumor necrosis factor. Hum Gene Ther.1992; 3: 57–73.
42.
GansbacherB., HoughtonA., LivingstonP.A pilot study of immunization with HLA-A2 matched allogeneic melanoma cells that secrete interleukin-2 in patients with metastatic melanoma. Hum Gene Ther.1992; 3: 677–690.
43.
GansbacherB., MotzerR., HoughtonA.A pilot study of immunization with interleukin-2 secreting allogeneic HLA-A2 matched renal cell carcinoma cells in patients with advanced renal cell carcinoma. Hum Gene Ther.1992; 3: 691–703.
44.
Ostrand-RosenbergS., ThakurA., ClementsV.Rejection of mouse sarcoma cells after transfection of MHC class II genes. J Immunol.1990; 144: 4068–4071.
45.
ChenL., AsheS., BradyW.A.Costimulation of antitumor immunity by the B7 counter-receptor for the T lymphocyte moleucles, CD28 and CTLA-4. Cell.1992; 71: 1093–1102.
46.
TownsendS.E., AllisonJ.P.Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science.1993; 259: 310–311.
47.
BaskarS., Ostrand-RosenbergS., NabaviN.Constitutive expression of B7 restores immunogenicity of autologous tumor cells expressing truncated major histocompatibility complex class II molecules. Proc Natl Acad Sci U S A.1993; 90: 5687–5690.
48.
OgasawaraM., RosenbergS.A.Enhanced expression of HLA molecules and stimulation of autologous human tumor infiltrating lymphocytes following transduction of melanoma cells with γ-interferon genes. Cancer Res.1993; 53: 3561–3568.
49.
RosenthalF.M., CroninK., BannerjiR.Augmentation of antitumor immunity by tumor cells transduced with a retroviral vector carrying the interleukin-2 and interferon-γ cDNAs. Blood.1994; 83: 1289–1298.
EshharZ., WaksT., GrossG.Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the γ or zeta subunits of the immunoglobulin and T cell receptors. Proc Natl Acad Sci U S A.1993; 90: 720–724.
52.
HwuP., ShaferG.E., TreismanJ.Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor γ chain. J Exp Med.1993; 178: 361–366.
53.
HwuP., RosenbergS.A.The genetic modification of T cells for cancer therapy: an overview of laboratory and clinical trials. Cancer Detect Prev.1994; 18: 43–50.
54.
NabelG.J., NabelE.G., YangZ.Y.Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. Proc Natl Acad Sci U S A1993; 90: 11307–11311.
55.
SorrentinoB.P., BrandtS.J., BodineD.Selection-of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDR1. Science.1992; 257: 99–103.
